. 2007 Aug 2;11(4):R84. doi: 10.1186/cc6089

Table 3.

Peak and Mean uNGAL concentrations by pRIFLEmax status

Measurement	Control	pRIFLEmax R	pRIFLEmax I	pRIFLEmax F
Mean uNGAL^a
ng/mg creatinine	0.5 ± 1.5/0.1 (0.2)	0.6 ± 0.9^b/0.3 (0.9)	1.7 ± 2.6^b/0.7 (1.8)	2.8 ± 3.0^b,c/1.5 (4.2)
ng/ml	14.2 ± 27.2/5.3 (13.2)	20.9 ± 28.1/11.6 (27.5)	58.9 ± 86.6^b/20 (71.4)	82.7 ± 92.5^b,c/35.0 (76.3)
Peak uNGAL^a
ng/mg creatinine	0.8 ± 2.0/0.2 (0.4)	1.0 ± 1.5^b/0.4 (1.2)	2.5 ± 3.8^b/0.9 (1.9)	3.8± 3.8^b,c/1.8 (5)
ng/ml	24.6 ± 45.5/7.9 (20.0)	34.5 ± 47.4/14.7 (40.5)	82.9 ± 122.9^b/25.0 (70.0)	103.2 ± 107.3^b,c/55.0 (105.0)

Values are expressed as mean ± standard deviation/median (interquartile range). ^aMean and peak urine neutrophil gelatinase-associated lipocalin (uNGAL) concentrations increased with worsening pRIFLEmax acute kidney injury (AKI; all P < 0.0002, Kruskal-Wallis test), whether expressed in ng/mg creatinine or ng/ml. These relationships were also statistically significant when examined by one-way analysis of variance (P < 0.0001). ^bMean and peak uNGAL expressed in ng/mg creatinine was higher in patients with pRIFLEmax R, I and F AKI than in control patients (all P < 0.05, Mann-Whitney test); mean and peak uNGAL expressed in ng/ml was higher in patients with pRIFLEmax R, I, and F AKI than in control patients (all P < 0.05, Mann-Whitney test). ^cMean and peak uNGAL was higher in patients with pRIFLEmax F AKI than in those with pRIFLEmax R and I AKI (all P < 0.05, Mann-Whitney test), whether expressed in ng/mg creatinine or in ng/ml. pRIFLEmax, the worst pRIFLE stratum attained; pRIFLE, pediatric modified Risk, Injury, Failure, Loss, End Stage Kidney Disease.